{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hussain I"],"funding":["Bill and Melinda Gates Foundation"],"pagination":["31"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12852092"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["Wild poliovirus remains endemic in Pakistan and Afghanistan despite global progress. We quantified immunity to poliovirus types 1-3 among children aged 6-23 months in 44 high-risk districts (2022-2023) using a cross-sectional serosurvey with probability proportional to size (PPS) cluster sampling. We enrolled 20,680 children (10,112 aged 6-11 months; 10,568 aged 12-23 months). Seroprevalence among 6-11-month-olds was 94.5% (type 1), 44.6% (type 2), and 88.0% (type 3); among 12-23-month-olds, it was 95.9%, 53.8%, and 91.2%, respectively. Type 1 seropositivity was highest across provinces; type 3 exceeded 90% except in Balochistan and KP; type 2 was lowest everywhere. Younger children have lower immunity. In multivariable models, residence in Balochistan predicted reduced seroprotection (AOR"],"journal":["NPJ vaccines"],"pubmed_title":["Progress and gaps in poliovirus immunity: Evidence from a serological survey of children aged 6-23 months in high-risk districts of Pakistan."],"pmcid":["PMC12852092"],"funding_grant_id":["OPP1156736"],"pubmed_authors":["Alam MM","Partridge J","Soofi S","Bosan A","Hafiz R","Sajid M","Hussain I","Khan A","Umer M","Abbas H","Haq MA"],"additional_accession":[]},"is_claimable":false,"name":"Progress and gaps in poliovirus immunity: Evidence from a serological survey of children aged 6-23 months in high-risk districts of Pakistan.","description":"Wild poliovirus remains endemic in Pakistan and Afghanistan despite global progress. We quantified immunity to poliovirus types 1-3 among children aged 6-23 months in 44 high-risk districts (2022-2023) using a cross-sectional serosurvey with probability proportional to size (PPS) cluster sampling. We enrolled 20,680 children (10,112 aged 6-11 months; 10,568 aged 12-23 months). Seroprevalence among 6-11-month-olds was 94.5% (type 1), 44.6% (type 2), and 88.0% (type 3); among 12-23-month-olds, it was 95.9%, 53.8%, and 91.2%, respectively. Type 1 seropositivity was highest across provinces; type 3 exceeded 90% except in Balochistan and KP; type 2 was lowest everywhere. Younger children have lower immunity. In multivariable models, residence in Balochistan predicted reduced seroprotection (AOR","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-12T10:19:04.993Z","creation":"2026-06-12T03:11:39.73Z"},"accession":"S-EPMC12852092","cross_references":{"pubmed":["41469400"],"doi":["10.1038/s41541-025-01352-1"]}}